Effects of oral contraceptives on the prevalence of alveolar osteitis after mandibular third molar surgery: a retrospective study

Almeida, Luís Eduardo; Pierce, Sean; Klar, Kevin; Sherman, Katherine

doi:10.1016/j.ijom.2016.05.022

Cited by 20 publications

(26 citation statements)

References 15 publications

(10 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to the present study, the risk of AO in females on OC drugs was almost double com pared to females not using OC drugs and males. This finding is consistent with some of the recently reported studies [11,12]. Several studies have reported no statisti cally significant difference in incidence of AO among fe males taking and not taking OC.…”

Section: Discussionsupporting

confidence: 93%

Incidence of alveolar osteitis in female patients on oral contraceptive drugs undergoing mandibular third molar surgery

Kumar¹,

Pisal²

2019

jos

View full text Add to dashboard Cite

Introduction: Alveolar osteitis is a common complication after tooth extraction. Risk of alveolar osteitis is rela tively higher following surgical removal of impacted mandibular third molars, as compared to normal extrac tion. Objectives: This study was conducted to evaluate the incidence of alveolar osteitis in females taking oral contra ceptive drugs. Material and methods: This retrospective study evaluated the incidence of alveolar osteitis in patients after surgical removal of mandibular 3 rd molar. Patient records were evaluated for demographic details, history of pro cedures, intake of oral contraceptive drugs during extraction, and complications. Data obtained from the ret rospective analysis was divided into male, females on contraceptives, and females not on contraceptive drugs. The incidence of alveolar osteitis was evaluated in these three groups. Results: Data of 660 patients who had undergone 3 rd molar surgery was evaluated, out of which 452 were male and 208 were female patients. Total of 42 female patients were on oral contraceptive drugs. 51 patients (7.72%) had alveolar osteitis on postoperative followup. Out of these 51 patients, 31 were males and 20 were females. Incidence of alveolar osteitis in females on oral contraceptive drugs was almost double as compared to females without contraceptive drugs and males. Conclusions: This study supported the hypothesis that oral contraceptive drug increases the risk of alveolar osteitis. However, our study was a retrospective analysis, therefore has certain limitations. A prospective research with grading of surgical difficulty could help to standardize these results.

show abstract

Section: Discussionsupporting

confidence: 93%

Incidence of alveolar osteitis in female patients on oral contraceptive drugs undergoing mandibular third molar surgery

Kumar¹,

Pisal²

2019

jos

View full text Add to dashboard Cite

show abstract

“…Eighteen studies [5][6][7][9][10][11]13,[15][16][17][18][19][20][21][23][24][25]27] examined the possible influence of gender on the prevalence of alveolar osteitis [ Figure 3]. Women had a 1.44-fold higher the risk of alveolar osteitis compared with men, with a statistically very significant relationship (OR = 1.44, 95% CI: 1.13-1.84, P < 0.01).…”

Section: Resultsmentioning

confidence: 99%

“…In this meta-analysis on the possible effect of OCs intake on oral tissues, data from 29 studies have been included in the study. Several studies [5][6][7][8][9][10][11][12][13][14][15][16][19][20][21][22][23][24][25][26][27] note a higher prevalence of alveolar osteitis in women taking OC than in those who do not, suggesting a possible direct link between OC intake and alveolar osteitis. According to the present study, women taking OC were 2.32 times more likely to suffer from alveolar osteitis with a statistically significant association (OR = 2.32, 95% CI: 1.96-2.74, P < 0.001).…”

Section: Discussionmentioning

confidence: 99%

“…A higher prevalence of alveolar osteitis in females than in males was found, with a statistically significant relationship (P < 0.01). Indeed, women Thirteen studies [7,9,[15][16][17][18][19][20][21][23][24][25]27] coincided in this predilection for the female gender; meanwhile, other five studies [5,6,10,11,13] did not find significant predilection for either gender. This higher prevalence of alveolar osteitis in women could be related to their OC intake.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Why screening and prophyl- axis remain to be vital components of oral cancer research?

Gupta¹,

Sivakumar²

2019

jodm

View full text Add to dashboard Cite

Background: Oral contraceptives (OCs) have been related to several systemic and oral diseases. Among oral diseases, the frequently encountered are periodontal diseases and alveolar osteitis. Objective: The objective of the study was to assess the possible association between OC and oral diseases. Materials and Methods: A PubMed search through 2018 considering the following medical subject headings terms "contraceptive agents" and "mouth diseases" was carried out. Studies with findings on OCs and mouth diseases were assessed. From 81 studies with full-text availability, 52 were excluded for several reasons: No clinical data (21), no usable/irrelevant data (26), and studies without a control group (5). Statistical Analysis: RevMan 5.3 statistical program was used to analyze the results. The odds ratio (OR) with the Mantel-Haenszel method (dichotomous data) and the mean difference with the inverse variance method (continuous data), both with 95% confidence intervals were utilized. Results: Main risk factors for osteitis alveolar were OC intake (OR: 2.32) and female gender (OR: 1.44). OC intake significantly influenced a greater bleeding on probing (P < 0.01) and a greater clinical attachment level loss (P = 0.03). On the contrary, it had no influence on other periodontal parameters such as plaque index, gingival index, or probing depth. Conclusions: OC intake is closely linked to the risk of alveolar osteitis and, to a lesser extent, to periodontal disease risk.

show abstract

“…It has been reported to occur more often following the extraction of impacted mandibular third molars. Studies have reported incidence rates as high as 37.5% following the surgical extraction of impacted lower third molars (1) . The denuded alveolar bone may be painful and tender.…”

Section: Introductionmentioning

confidence: 99%

Local use of antifibrinolytic agent in prevention of alveolar osteitis (A clinical study)

Ali

2017

Egyptian Dental Journal

View full text Add to dashboard Cite

The study was done to evaluate the effect of local use of antifibrinolytic agent in the prevention of alveolar osteitis after extraction of impacted mandibular 3 rd molar. The study took place on 90 consecutive patients (45 patients in each group). After surgical extraction the sockets were irrigated immediately with 10ml of solution (tranexamic acid or placebo) for 2 min. 4 times / day (every 6 hours) for 2 days. Patients returned in five to seven days for suture removal complaining of postoperative pain were examined to verify the severity of the localized osteitis which graded as mild, moderate, or severe according to the patient's stated degree of pain which scored according to visual analogue scale .The incidence of dry sockets in the group treated with 10% tranexamic acid was 6.6% compared with 28.8% in the sockets treated with placebo. In addition, the untreated group presented with dry sockets judged to be more severe.

show abstract

Effects of oral contraceptives on the prevalence of alveolar osteitis after mandibular third molar surgery: a retrospective study

Cited by 20 publications

References 15 publications

Incidence of alveolar osteitis in female patients on oral contraceptive drugs undergoing mandibular third molar surgery

Incidence of alveolar osteitis in female patients on oral contraceptive drugs undergoing mandibular third molar surgery

Why screening and prophyl- axis remain to be vital components of oral cancer research?

Local use of antifibrinolytic agent in prevention of alveolar osteitis (A clinical study)

Contact Info

Product

Resources

About